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ABSTRACT 
 
CYANATE FORMATION FOLLOWING 2-CHLOROACRYLONITRILE EXPOSURE 
AND THE ROLE OF CYTOCHROME P-450 
 
 
 
By 
Paul Malichky 
May 2011 
 
Dissertation supervised by David A. Johnson, Ph.D. 
2-Chloroacrylonitrile (2-CAN) is a volatile, toxic chemical used as a raw material to 
manufacture pesticides.  Although the toxic mechanism is not fully understood, the 
hypothesis in the literature is that 2-CAN may be metabolized to cyanide.  An 
understanding of the mechanism of 2-CAN toxicity will permit more appropriate 
treatments in the event of an accidental exposure. 
Four groups of male Sprague-Dawley rats were given intraperitoneal (i.p.) 
injections.  Group 1 was a control that received only saline.  Group 2 received 40 mg/kg of 
2-CAN.  Group 3 received 100 mg/kg of 5-phenyl-1-pentyne (5P1P) an inhibitor of 
cytochrome P-450.  Group 4 received 100 mg/kg of 5P1P one hour before 40 mg/kg of 2-
CAN. Three hours following administration, the animals were euthanized via cardiac 
puncture. Cardiac blood was collected for cyanide and cyanate analysis. Liver and lung 
 v 
 
tissues were harvested and analyzed for glutathione.  In a separate experiment, the time to 
onset of hind limb paralysis was measured in animals receiving 40 mg/kg 2-CAN and 100 
mg/kg 5P1P one hour prior to 40 mg/kg 2-CAN. 
Blood cyanide levels were increased in the 2-CAN group, but did not exceed 0.06 
µg/mL, a concentration well below the minimum for producing adverse health effects.  
Compared to control animals, the 2-CAN treatment group had depleted  glutathione by 
20% in the lung and 44% in the liver.  When 5P1P was administered prior to 2-CAN, there 
was no significant change in glutathione concentrations. 
Plasma cyanate levels in the 2-CAN group were 436 nmol/L plasma, a 390% 
increase over control.  When a 5P1P was administered prior to 2-CAN, cyanate levels were 
reduced by 55% to less than 195 nmol/L plasma.  In addition to decreasing plasma cyanate 
levels, 5P1P 1 hour prior to 2-CAN delayed the onset of hind limb paralysis from 6 minutes 
to 16 minutes. 
Since cyanide was not generated in substantial concentrations following 2-CAN 
administration, the use of an antidote specific for cyanide for 2-CAN toxicity may not be 
effective.  The findings of increased cyanate levels in 2-CAN, combined with the hind-limb 
paralysis data suggest that cyanate, not cyanide, is the toxic metabolic product resulting 
from acute 2-CAN exposure.   
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I. Introduction 
 
A. Statement of the Problem 
 
2-Chloroacrylontrile (2-CAN) is an industrial chemical used in the manufacture of 
pesticides.
1
  It is also used in the manufacturing process of norepinephrine reuptake 
inhibitors.
2
   
An acute inhalation study indicated the LC50 value in rats was 28 ppm for a 4 hour 
exposure.
3
  The LC50 is the airborne concentration in which 50% of the animals die.  An 
LC50 of 28 ppm is classified as highly toxic.
4
  2-CAN is also toxic via the oral and dermal 
routes.  The oral LD50 in rats is 32-78 mg/kg, the dermal LD50 is approximately 200 
mg/kg in rats and less than 220 mg/kg in the rabbit.
5
  In addition to lethality, the 
compound is also highly irritating
5
 and a severe respiratory irritant.  The RD50 is the 
concentration for which there is a 50% decrease in respiratory rate and is an indictor of 
sensory irritation.  The RD50 value for 2-CAN is 5.7 ppm.
6
 
In addition to being highly toxic, 2-CAN is also highly volatile with a vapor pressure 
of 85.4 mbar at 25°C.
5
    For comparison, this makes 2-CAN slightly more volatile than 
ethanol which has a vapor pressure of 79.1 mbar at 25°C.
7
  Although the compound is 
used as an industrial intermediate in a closed process, it should be considered a high risk 
chemical due to the high toxicity and high exposure potential.  If there were a 
transportation incident or release at a production facility, it would be critical to know how 
to best treat people that were exposed. 
  2 
Although it is known that 2-CAN is highly toxic, the mechanism of toxicity is not 
well understood.  In cases of human exposure, the manufacturer’s Material Safety Data 
Sheet (MSDS) recommends treatment for cyanide toxicity.
5
  The traditional treatment for 
cyanide toxicity is sodium nitrite combined with thiosulfate.
8
  In this treatment, 
hemoglobin is oxidized to methemoglobin which then scavenges cyanide.
9
  Although it 
may be effective in saving a person’s life in an emergency cyanide poisoning situation, 
this antidote is also a very risky treatment because methemoglobin reduces the body’s 
ability to carry oxygen to the cells.
10
 
 An unpublished study by the manufacturer (Bayer) exposed four beagle dogs to 2-
CAN at 97 mg/m3 for one hour.  There was little effect on the dogs with no fatalities.  
There were no abnormalities in arterial blood gases and there were no abnormal findings 
in the lungs.  However, microscopic examination of lung tissue did indicate evidence of 
inflammation and focal pulmonary edema.  There was also a slight increase in plasma 
thiocyanate.  This could suggest liberation of cyanide, but the increases were not 
statistically significant or toxicologically relevant.
11
 
  The hypothesis to be tested in this research dissertation is that the neurotoxicity 
of 2-CAN is primarily the consequence of the metabolite cyanate not cyanide.  
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B. Literature Survey 
1. Compounds chemically similar to 2-CAN 
A review of the literature suggests there is little known mechanistically about 2-CAN 
toxicity, but there is information that is known about other compounds similar to 2-CAN.  
The most common nitrile compounds are acrylonitrile (AN) and methacrylonitrile 
(MAN).  Figure 1 shows the structural similarities.   
 
Figure 1. Structure of Acrylonitrile (AN), Methacrylonitrile (MAN), and 2-
chloroacrylonitrile (2-CAN) 
 
  4 
Figure 2 shows the relative toxicity of the nitriles.  2-CAN is more toxic than AN.  
AN is more toxic than MAN. (Figure 2) 
 
Figure 2 – LD50 of AN, MAN, 2-CAN 
Chemical Oral LD50 (rat) i.p. LD50 (rat) 
Acrylonitrile 78 mg/kg
12
 65 mg/kg 
Methacrylonitrile 200 mg/kg
13
  
2-Chloroacrylonitrile 32-72 mg/kg
5
 14-20 mg/kg
14
 
 
 
Acrylonitrile (AN) 
Billions of pounds of AN are produced annually.
15
  It is used for the production of 
plastics and resins.
15
   Acrylonitrile is a known rat carcinogen and suspected human 
carcinogen.
15
   
There are two major metabolic pathways for acrylonitrile in the rat.  The first is 
conjugation with reduced glutathione (GSH).
16
  The AN-GSH conjugate is then 
processed in the mercapturic acid pathway and excreted in the urine.
17
 
18
 
19
  More than 
50% of AN is excreted via the urine
20
 and less than 11% in the expired air.
21
  The second 
metabolic pathway is cytochrome P450-mediated oxidation to the AN-epoxide 2-
cyanoethylene oxide (CEO).
16
 
22
 
23
  CEO is considered to be the carcinogen derived from 
AN.
24
  Some of the epoxide is then further conjugated with glutathione and excreted via 
the mercapturic pathway and ultimately eliminated via the urine.
20
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Acrylonitrile is known to cause glutathione depletion.
25
  Glutathione protects cells 
from AN toxicity until it is depleted.  Thereafter, AN covalently binds to proteins in the 
cell.
26
  One treatment for AN exposure is thiol-containing compounds such as n-acetyl-l-
cysteine (NAC).  The thiol can directly react with AN and prevent it from reacting with 
critical sulfhydryl groups in the body.
27
  The thiol-AN conjugate would then be excreted 
in the urine via the mercapturic acid pathway.  A second benefit of the thiol compound is 
as a precursor for the synthesis of GSH depleted by AN.
27
  Treatment with GSH is not 
effective since GSH does not cross the cell membrane.  NAC has been proven to be 
effecting in replenishing GSH levels and reducing toxicity in acetaminophen overdoses.
28
  
29
  A third benefit of the thiol is as a sulfur source for cyanide metabolism.  The normal 
metabolism of cyanide involves the formation of thiosulfate.  When glutathione levels in 
rats were depleted, there was an increased amount of AN binding to tissues and an 
increase by 300% in thiocyanate, a metabolite from the epoxide mechanism.
30
  To form 
thiosulfate, a sulfur donor is needed for the rhodanese enzyme.  Cysteine and its analogs 
can act as a sulfur donor
31
 and decrease the amount of free cyanide.
27
  Treatment of AN 
with cysteine and its n-acetyl derivates does not change the amount of non-oxidative 
mercapturic acid metabolites, but does decrease blood cyanide levels and the overall 
toxicity of AN.
27
 
32
  For these reasons, the German government recommends high 
intravenous doses of NAC as a treatment for accidental overexposure to AN by 
workers.
33
 
Acrylonitrile leads to the generation of cyanide
26
 
27
, but acrylonitrile must first be 
metabolized by the cytochrome P450 oxidase CYP2E1 to the epoxide before cyanide is 
generated.
34
  With CYP2E1 induction, cyanide levels increase in a dose dependent
35
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fashion, and following CYP2E1 inhibition cyanide levels decrease.
34
 
36
 Induction of 
CYP2E1 increased cyanide levels and caused lethality at a dose not normally fatal.
36
  
Cyanide released from AN is considered to be a major contributing factor in AN-induced 
lethality
37
 and human intoxication from AN exposure has been successfully treated with 
cyanide antidotes.
38
  The conversion of AN to cyanide is also route dependent.  The 
slower the rate of absorption, the more cyanide is generated from the same dose 
(intravenous<subcutaneous<intraperitoneal<oral).
39
 The addition of glutathione or 
cysteine decrease the amount of cyanide generated from AN administration.
40
   
Recent studies indicate CYP 2E1 is the specific CYP involved in the formation of 
the epoxide. 
20
 
34
 
35
 
41
 
42
  When rats were pre-treated with a CYP inhibitor, the amount of 
AN excreted in the urine decreased, and the total retention of AN in the animal 
increased.
21
  Following administration of AN in CYP2E1-null mice, the cyanide levels 
were nearly undetectable and did not increase when the dose of AN was increased.
35
 
43
  
Following 40 mg/kg AN administered via gavage, all wild-type mice died within 3 hours 
while CYP2E1-null mice were able to survive 60 mg/kg/day for 5 day/week for 6 
weeks.
35
  When mice were treated with a CYP2E1 inhibitor or CYP2E1 null mice or 
were administered AN, there were no metabolites derived from the epoxide.
41
  When 
CYP2E1 activity is induced by repeated acetone administration, there was an increase in 
mortality and lung damage following a single dose of AN.
44
  Sub-chronic inhalation or 
sub-chronic high-dose oral administration of AN resulted in hind limb weakness which 
was only partially reversible.
45
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Methacrylonitrile (MAN) is used as a replacement for acrylonitrile (AN) in the 
production of plastics and resins.
46
  It is also a component of the smoke from unfiltered 
cigarettes.
47
 
Methacrylonitrile (MAN) is excreted much faster than acrylonitrile (AN)
21
 and 
excreted via the lung to a greater extent.
21
  MAN urinary metabolites are more associated 
with the epoxide.
21
  MAN excreted via the lungs is either after epoxide formation or 
unchanged MAN.
48
  Lung tissues also show high levels of MAN at an early time period 
(5 min).
12
  Following oral administration, excretion is rapid up to a dose of 29 mg/Kg 
after which excretion mechanism(s) become saturated and elimination is greatly 
slowed.
49
   
MAN is metabolized by cytochrome p-450 enzymes to the epoxide intermediate 
1-cyano-1-methoxyloxirane.
50
  At the same dose in mice, MAN produces more cyanide 
than acrylonitrile.
51
  When MAN was administered to CYP2E1-null mice, there was 
reduction in cyanide formed
51
 while AN administered to the CYP2E1-null mice nearly 
eliminated the cyanide formation.
51
  When a CYP inhibitor not specific to 2E1 was given 
prior to the MAN administration to the CYP2E1 null mice, this nearly eliminated the 
cyanide formation.
51
  This suggests that cyanide formation in MAN is not specific to 
CYP2E1 and that other cytochrome p-450 microsomes are involved in the metabolism of 
MAN.
51
 
MAN is known to induce neurotoxicity in rats
52
 although sub-chronic oral 
administration of MAN did not result in observed hind limb paralysis.
45
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Figure 3 - Proposed mechanism of methacrylonitrile (MAN)
48
 
 
 
Cyanate 
Cyanide (CN) is normally metabolized to thiocyanate (SCN
-
) via the sulfur-dependent 
enzyme rhodanese
53
 and then excreted in the urine.  When sulfur amino acids are not 
readily available, cyanide may be converted to cyanate, which is known to cause 
neurologic effects in humans and animals
53
. (Figure 4) 
  9 
Figure 4. Metabolism of cyanide 
 
 
Sodium cyanate is known to increase hemoglobin’s affinity for oxygen and at one 
point was considered as a treatment for sickle cell anemia.
54
  Sodium cyanate acts by 
carbamylation of the amino terminal valine of hemoglobin.  Early oral studies showed no 
adverse effects in monkeys or dogs to either sodium cyanate or potassium cyanate.
55
  
People administered sodium cyanate for extended periods as a possible treatment for this 
disease developed motor and sensory neuropathy.
56
  Also, monkeys receiving 
intramuscular injection of sodium cyanate were found to have permanent hind limb 
paralysis.
57
  Table 1 indicates there is little difference in the toxicity of sodium cyanate 
and potassium cyanate and they are often used interchangeably in studies. 
Table 1 – Comparison of LD50 of sodium and potassium cyanate. 
Compound  LD50 Route Species 
Sodium cyanate 260 mg/kg
55
 i.p. Mouse 
Potassium cyanate 320 mg/kg
55
 i.p. Mouse 
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Spastic paraparesis is also observed in communities in Africa, presumably due to 
eating Cassava, a plant that contains cyanide.
58
 
59
 
60
  In all cases, the onset was rapid.  
The effects were also permanent.
61
  High cyanide intake combined with deficient sulfur 
intake impairs the cyanide to thiocyanate conversion.
59
   
Sodium cyanate is able to cross the blood brain barrier.  After i.p. administration of 
radio-labeled sodium cyanate in rats, it was detected in the cerebrospinal fluid (CSF).  
Within 24 hours, the compound was not found in the CSF suggesting cyanate was 
metabolized and excreted.
62
  Sodium cyanate also has a direct effect on glutathione levels 
resulting in a 50% decrease in brain GSH concentration within 15 minutes and a 35% 
decrease in liver GSH levels.
53
  Following a single dose of cyanate, the physiological 
effects range from restlessness at low doses, to hind limb paralysis at medium doses, to 
noise triggered convulsive seizures at high concentrations.
63
  Rats administrated sodium 
cyanate i.p. for extended periods were also noted to have weakness, particularly of the 
hind limbs.
64
  In humans and rats, the effects of sodium cyanate were not noted for weeks 
or months after administration.  The onset of hind limb paralysis is dose dependent in 
rats.
65
  Even on a diet consisting of low sulfur amino acids (SAA), rats still took two days 
before hind limb paralysis was observed.
66
 
Rats were fed a diet of low sulfur amino acids or a normal diet and then given water 
that contains potassium cyanide.  Over the next four weeks, cyanide, cyanate, and 
thiocyanate levels were measured.  Thiocyanate levels did not change over time or 
between the groups.  With the SAA-free diet, there was only a small change in cyanide 
levels after 4 weeks.  Cyanate levels were consistent with both groups for the first two 
  11 
weeks, but the concentration of plasma cyanate in the SAA-free group increased 
exponentially in weeks three and four.  The final concentration of cyanate blood plasma 
level was 113 nmol/L in the SAA-free diet compared to 29 nmol/L in the regular diet 
group.
53
  No hind-limb effects were noted.  The authors’ suggested this was due to the 
study being terminated prior to the limit of cyanide metabolism via thiocyanate being 
sufficiently saturated.
53
  This result suggests that in rats, cyanide can be converted to 
cyanate.  It also shows that with a low sulfur diet, the levels of cyanate were higher.  
When rats were fed a cyanate-rich diet for 18 months, all developed motor weakness.  
The cause was determined to be damage to the myelin sheath, especially the sciatic 
nerves.
67
  More recently, sodium cyanate has been shown to cause an increase in the open 
probability of large conductance calcium-activated potassium channels (BKCa) in 
hippocampal neuron-derived cells.
68
  These channels are also referred to as high-
conductance calcium-activated potassium (maxi-K) channels.  Increasing the opening of 
these channels would result in a decrease in neuronal excitability. 
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Glutathione 
Reduced glutatione is a critical cellular antioxidant consisting of the tripeptide  
y-glu-cys-gly (Figure 5).
69
 
Figure 5. Structure of reduced glutathione (GSH) 
 
 
           y-glu                         cys                    gly 
Reduced glutathione is typically present in concentrations ranging from 0.1-10 mM 
and is the most prevalent thiol and the most abundant low molecular weight peptide.  In 
many cells, GSH accounts for over 90% of the total non-protein sulfur.
70
  Extensive cell 
damage or cell death will occur if there is not a sufficient supply of GSH.
71
  The first 
function of GSH is to donate a hydrogen ion to unstable molecules such as reactive 
oxygen species.  As noted in figure 6, two molecules of GSH react to form the oxidized 
form of glutathione (GSSG).  
  13 
Figure 6. Structure of oxidized glutathione (GSSG) 
 
 
 
 
 
 
Another function of GSH is direct conjugation with compounds.  During this process, 
GSH directly binds to the compound and the conjugate is excreted in the urine as 
mercapturic acid metabolites.  
Because GSH is so critical to normal cellular function, there is a substantial ability for 
the cells to produce GSH.  The rate limiting step in the synthesis of GSH is the quantity 
of available cysteine.
72
   Figure 7 describes the mechanism for the synthesis of GSH 
Figure 7 – Synthesis of GSH73 
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Increasing cellular GSH levels is not possible via administration of GSH.
74
  This is due to 
extracellular metabolism and the inability of GSH to cross the cell membrane.  A more 
effective way to increase the amount of cellular GSH is to increase the amount of 
cysteine available for the cell to produce its own GSH.  As an example, it is known that 
hepatic damage caused by acetaminophen is GSH-dependent.
75
  Pre-treatment with a 
compound known to deplete GSH increased hepatic necrosis in mice.
75
  Pretreatment 
with cysteine, which is known to increase GSH synthesis, results in a reduction in hepatic 
damage.
75
  Only when GSH is severely depleted (greater than 75%), do acetaminophen 
metabolites covalently bind to other hepatic macromolecules.   
Cytochrome P-450 
In addition to changes in glutathione levels, it is expected that oxidation may play an 
important role in the toxic mechanism of 2-CAN.  Cytochrome P-450 (CYP) is a 
superfamily of hemoproteins which are catalysts for the oxidative metabolism of many 
compounds (endogenous and exogenous) including testosterone, chlorzoxazone, and 
coumarin.
76
  There are dozens of subtypes of CYPs.  One way to divide the category of 
P-450 cytochromes is by family.  For example, the CYP2 is associated with drug and 
steroid metabolism.  The family is further divided into subfamilies based on the genes 
that code each protein.  For example, the CYP2E1 protein is encoded by the CYP2E1 
gene. 
CYP2E1 concentrations are highest in the liver with lower levels in other tissues.
77
  
CYP2E1 is involved in the metabolism of alcohol to acetaldehyde
78
, but has a much 
lower affinity than alcohol dehydrogenase.
79
  The interaction with alcohol is important 
because alcoholics can have CYP2E1 induced by a factor of 3-5.
80
  There is also a large 
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variation in CYP2E1 activity among people from different ethnic backgrounds, and even 
specific polymorphisms within ethnic groups.
79
  Persons with slower CYP2E1 activity 
have higher acrylonitrile adduct levels due to less acrylonitrile being oxidized.
81
    
In order to limit other potential biological effects of inhibiting multiple CYP 
subtypes, we needed to select as specific an inhibitor as possible.  5-phenyl-1-pentyne 
(5P1P) is an inhibitor of CYP2E1 in rat liver.
82
  5P1P is also an inhibitor of CYP2F2, or a 
mixed inhibitor of CYP2E1 and CYP2F2.
83
 
84
 
85
  The designation of 5P1P as an inhibitor 
of CYP2F2 is based on the effects of 5P1P which are similar to effects observed in 
CYP2E2 knockout mice.
86
   5P1P is sometimes administered for weeks, but the least 
amount of time noted in any study was 1 hour prior to administration of the test 
compound.
83
  Based on a phone discussion with one of the authors (GP Carlson), 100 
mg/kg for 1 hour was selected because it would be sufficient for some inhibition without 
overloading the animal and causing unintended effects.
87
   
Several drugs approved for use in humans are known to inhibit cytochrome P-450 
including: chlorpromazine, diclofenac, fluphenazine, thioridazine, isoniazid, diallyl 
sulfide, 4-methyl pyrazole, and disulfiram.
88
  Some antifungal azoles, antidepressants, 
(phenothiazine antipsychotics), benzodiazepines (flurazepam, medazepam) and non-
steroidal anti-inflammatory drugs (Diclofenac and Flufenamic acid) are known to have 
specificity for CYP2E1.
89
  In humans, isoniazid has been shown to be an inhibitor of 
CYP2E1 and, when administered after acetaminophen, reduce the formation of 
acetaminophen thioether metabolites.
90
   
Cyanide 
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Cyanide is known to be very toxic in humans and animals.  Under normal 
biological metabolism, cytochrome oxidase a3 is needed to transfer electrons from 
NADH to oxygen in the mitochondria.  The cyanide ion inhibits this enzyme by binding 
to the ferric ion found in the enzyme.  This prevents the transport of electrons by 
cytochrome a3 oxidase to oxygen.  This results in the cell no longer being able to 
aerobically produce ATP.  Depending on severity, this effect could cause cell damage, 
tissue damage, or death.
10
  See table 2 for blood concentrations and their effects noted in 
humans. 
Table 2 Blood concentrations of cyanide and associated clinical effects in 
humans
91
 
Cyanide Concentration (µg/mL) Signs and symptoms 
0.2 – 0.5 None 
0.5 – 1.0 Flushing, tachycardia 
1.0 – 2.5 Lack of alertness and orientation 
2.5 – 3.0 Coma 
>3 Death 
 
Cyanide metabolism is very rapid.  In rats, maximum cyanide concentration is 
observed in 15 minutes while the maximum thiocyanate level is observed in 6 hours.
92
  
Cyanide is also known to induce rhodanese
93
, the main enzyme in the thiocyanate 
detoxification pathway.  (See Figure 4) Therefore with low level chronic exposure, the 
amount of cyanide the body can metabolize is increased. 
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The traditional treatment for cyanide poisoning is a combination of amyl nitrite, 
sodium nitrite, and sodium thiosulfate.  The amyl nitrite and sodium nitrite generate 
methemoglobin which then competes with cytochrome c for cyanide.  This is the rapid 
response to cyanide poisoning, but is dangerous because methemoglobin decreases the 
body’s ability to transport oxygen.  Sodium thiosulfate converts cyanide to cyanate and is 
excreted in urine as mercapturic acid metabolites as described previously.  The FDA 
recently approved a new cyanide antidote kit (Cyanokit) which contains 
hydroxocobalamin, a vitamin B12 precursor.  Hydroxocobalamin directly binds to 
cyanide to form cyanocobalamin (vitamin B12).
94
  It does not have the side effects 
associated with the traditional treatment, but it does interfere with many other drugs and 
clinical tests. 
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Materials and Methods 
A. Materials and Equipment 
1. Facilities 
Laboratories – Mellon Hall, Room 405, 419a, and 456 
Office – Mellon Hall, Room 419 
Animal Care – Animal Care Facility, Bayer Learning Center, Basement 
Animal Prep – Animal Care Facility, Bayer Learning Center, Macro surgery 
Room 
 
2. Animals 
For all glutathione, cyanide, and cyanate experiments, male Sprague-
Dawley rats were obtained from Hilltop Lab Animals, Inc., Scottdale, 
Pennsylvania.  Initial weight was 200-250g.  Animals were given at least one 
week to acclimate prior to the start of experiment.  The animals were housed in a 
temperature and humidity controlled facility on a 12 hour light/dark cycle.  The 
temperature range was 64-79 
o
 C and the humidity range between 30-70%.  Rats 
were provided Purina Rat Chow #5001 and water ad libitum. 
For the hind limb paralysis experiments, male Sprague-Dawley rats 
originally obtained from Charles River Laboratories International, Inc. were bred 
at Duquesne and offspring were used.  Animal weight at the time of the 
experiments was 350-550 g.  Animals were given at least one week to acclimate 
prior to the start of experiments.  The animals were housed in a temperature and 
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humidity controlled facility on a 12 hour light/dark cycle.  They were provided 
Purina Rat Chow #5001 and water ad libitum. 
 
3. Chemicals 
1-Fluoro-2,4-Dinitrofluorobenzene 
Sigma Chemical Co., St. Louis, MO. 
 
2-Chloroacrylonitrile (2-CAN) 99% 
Aldrich Chemical Co., Milwaukee, WI. 
 
Acetic Acid, Glacial, ACS reagent, >99.7% 
Sigma-Aldrich, St. Louis, MO. 
 
Acetic Acid, Sodium Salt Trihydrate, Anhydrous 
Fisher Scientific Co., Pittsburgh, PA. 
 
Ethyl alcohol, absolute, 200 proof, 99.5% ACS reagent 
Aldrich Chemical Co., Milwaukee, WI. 
 
Barbituric Acid 
Fluka - Sigma Aldrich, St. Louis, MO. 
 
Bathophenathroline Disulfonic Acid (DL-Buthionine-[S,R]-sulfoximine) 
Sigma Chemical Co., St. Louis, MO 
 
Chloramine-T 
Riedel-de Haen, Honeywell 
 
-glutamyl glutamate 
Sigma Chemical Co., St. Louis, MO. 
 
-glutamyl glutamate 
MP Biomedicals, LLC, Solon OH 
 
BD Vacutainer Sodium Heparin (NH) 143 USP Units plus blood collection tubes 
BD., Franklin Lakes, NJ 
 
M-Cresol Purple Indicator Grade 99.8% 
Sigma Chemical Co., St. Louis, MO. 
 
Methanol, CHROMASOLV plus, for HPLC, > 99.9% 
Sigma-Aldrich, St. Louis, MO. 
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Perchloric Acid, 70%, ACS reagent 
Sigma-Aldrich, St. Louis, MO. 
 
Potassium Hydroxide Reagent ACS (Pellets) 
Fisher Scientific Co., Pittsburgh, PA. 
 
Potassium Hydrogen Carbonate 
Fisher Scientific Co., Pittsburgh, PA. 
 
Sodium Chloride 0.9% 
Baxter Medical Supplies, Deerfield, IL. 
 
Sodium Hydroxide Pellets 
Sigma-Aldrich, St. Louis, MO. 
 
10M Sodium hydroxide solution 
 
Sodium Phosphate Monobasic Dihydrate 
Fisher Scientific Co., Pittsburgh, PA. 
 
Ethyl acetate, 99.5+%, ACS reagent 
Sigma-Aldrich, St. Louis, MO. 
 
Hydrochloric Acid, Certified ACS 
Fisher Scientific Co., Pittsburgh, PA. 
 
Sulfuric Acid, 95-98%, ACS reagent 
Sigma-Aldrich, St. Louis, MO. 
 
Water, HPLC Grade 
Sigma Chemical Co., St. Louis, MO. 
 
Potassium Cyanide 
Sigma-Aldrich, St. Louis, MO. 
 
Pyridine, 99+%, ACS reagent 
Sigma-Aldrich, St. Louis, MO. 
 
Ammonium Hydroxide, certified ACS Plus 
Fisher Scientific Co., Pittsburgh, PA. 
 
Iodoacetic Acid, sodium salt >98% 
Sigma Chemical Co., St. Louis, MO. 
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Glutathione, Reduced, 98% 
Sigma Chemical Co., St. Louis, MO. 
 
Glutathione, Oxidized, 98% 
Sigma Chemical Co., St. Louis, MO. 
 
Potassium phosphate, Dibasic, Anhydrous 
Sigma Chemical Co., St. Louis, MO. 
 
Sodium Phosphate, Dibasic, Anhydrous Enzyme Grade 
Fisher Scientific, Pittsburgh, PA 
 
Benzoyleneurea, 97% 
Aldrich, St. Louis, MO. 
 
5-phenyl-1-pentyne, 98+% 
Lancaster Synthesis, Inc., Pelham NH 
 
Isoflurane (Aerrane)  
Baxter Healthcare, Deerfield, IL 
 
Potassium cyanate 
Fluka - Sigma Aldrich, St. Louis, MO. 
 
Anthranilic Acid 
Fluka - Sigma Aldrich, St. Louis, MO. 
 
Liquid Nitrogen 
Airgas Inc., Radnor, PA. 
 
Sodium Acetate, trihydrate 
Acros, Thermo Fisher Scientific, Rochester, NY 
 
 
4. Materials 
 
20 mL Cryogenic specimen containers (Nalgene) 
Fisher Scientific Co., Pittsburgh, PA. 
 
Mortar and pestle 
Duquesne University, Pittsburgh, PA. 
 
1.5 mL Microcentrifuge tubes 
Fisher Scientific Co., Pittsburgh, PA. 
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2.0 mL Microcentrifuge tubes 
Fisher Scientific Co., Pittsburgh, PA. 
 
20 l, 100 l, 200 l and 1000 l Micropipettes 
Rainin Instrument Co., Woburn, MA. 
 
200µLand 1000µLMicropipette tips 
Rainin Instrument Co., Woburn, MA. 
 
Conway microdiffusion dishes 
Duquesne University, Pittsburgh, PA. 
 
5 mL Volumetric flasks 
Fisher Scientific Co., Pittsburgh, PA. 
 
Falcon Blue Max Jr. 15mL polypropylene conical tube (17x20 mm) 
Becton Dickinson Labware, Franklin Lakes, NJ 
 
Fisherbrand Disposable Culture Tubes, Borosilicare Glass (12x75 mm) 
Fisher Scientific Co., Pittsburgh, PA. 
 
Varian Bond Elut Solid Phase Extraction Mega BE-PRS, 1GM, 6ML 
Varian Inc., Santa Clara, CA 
 
Waters Sep-Pak Vac 6cc (500 mg) C18 Cartridges 
Waters Corporation, Milford, MA. 
 
Minisart 0.45um single use syringe filter, hydrophilic 
Vivascience, Hannover Germany 
 
Pierce screw Cap Septum Vials 
Pierce Biotechnology, Rockford IL 
 
Durapore membrane filters, 0.45um HV 
Millipore, Billerica, MA 
 
10cc syringe with luer-lok tip 
Becton Dickinson, Franklin Lakes, NJ 
 
Kimble Glass tubes, culture, S/T, R.B. 16x25mm 
Thermo Fisher Scientific, Rochester, NY 
 
Fisher Brand Glass, serological pipets, 10mL 
Fisher Scientific Co., Pittsburgh, PA. 
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Millipore polypropylene filters (type HV, pore size 0.45 m) 
Fisher Scientific Co., Pittsburgh, PA. 
 
 
5. Equipment 
 
HPLC column: 20-cm  4.6-mm-i.d. column with 5-m Exsil silica 
derivatized with 3-aminopropyltriethoxy silane 
CEL Associates, Houston, TX. 
 
 HPLC column for glutathione: 3-aminopropyl, 5um 
 Custom LC, Inc., Houston TX 
 
 HPLC column for cyanate: Kromasil 100-5C18 25cm x 4.6mm (i.d.) 
 HiChrom Limited, Reading England  
 
 HPLC prefilter for cyanate: Kromasil 
 HiChrom Limited, Reading England  
 
Waters 510 HPLC Pump 
Waters Corporation, Milford, MA. 
 
Waters 501 HPLC Pump 
Waters Corporation, Milford, MA. 
 
Waters Automated Gradient Controller 
Waters Corporation, Milford, MA. 
 
Perkin Elmer 785A UV/Vis detector 
Perkin Elmer, Norwalk, CT. 
 
Perkin Elmer Series 200 Fluorescence detector 
Perkin Elmer, Norwalk, CT. 
 
Perkin Elmer Series 200 Autosampler 
Perkin Elmer, Norwalk, CT. 
 
Perkin Elmer Nelson Network Chromatography Interface 
Perkin Elmer, Norwalk, CT. 
 
Dell OptiPlex GX1 
Dell Corporation, Austin, TX 
 
1L Vacuum filtration flask 
Fisher Scientific Co., Pittsburgh, PA. 
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Millipore filtration apparatus (to vacuum flask) 
Fisher Scientific Co., Pittsburgh, PA. 
 
Pierce Reacti-Therm III heating module 
Pierce Corporation, Rockford, IL 
 
Pierce Reacti-Vap II 
Pierce Corporation, Rockford, IL 
 
Varian Cerex SPE processor 
 
Corning pH meter 220 
Corning Corporation, Corning, NY 
 
Fisher Scientific Marathon 16KM centrifuge 
Fisher Scientific Co., Pittsburgh, PA. 
 
Fisher Scientific Centric Centrifuge 
Fisher Scientific Co., Pittsburgh, PA. 
 
Reliable Scientific shaker 
Reliable Scientific Inc, Nesbit, MS 
 
Fisher Scientific ACCU-124 balance 
Fisher Scientific Co., Pittsburgh, PA. 
 
Beckman DU-530 Life Science UV/Vis Spectrophotometer 
Beckman Coulter, Danvers, MA 
 
Precision Reciprocal Shaking Bath 
Thermo Fisher Scientific, Rochester, NY 
 
Fischer Scientific Sonic Dismembrator model 100 
Fisher Scientific Co., Pittsburgh, PA. 
 
Isoflurane vaporizer 
A.M. Bickford, Wales Center, NY  
 
 
6. Computer Software 
 
Microsoft Word 
Microsoft Corporation, Redmond, WA 
 
Microsoft Excel 
Microsoft Corporation, Redmond, WA 
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Microsoft Powerpoint 
Microsoft Corporation, Redmond, WA 
 
Turbochrom Version 6.3.2 
Perkin Elmer, Waltham, Massachusetts 
 
GraphPad Prism 5 for Windows 
GraphPad Software, La Jolla, California 
 
Chem Draw 3D Pro 12.0 
CambridgeSoft, Cambridge, Massachusetts  
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B. Methodology and Procedures 
 
 
1. Hypothesis 
Hind limb paralysis resulting from acute 2-CAN exposure is the result of cyanate 
formation.  Blockade of 2-CAN metabolism by cytochrome P-450 enzyme inhibition 
utilizing 5P1P will attenuate 2-CAN toxicity. 
2. Specific Aims 
a. Determine whether cyanate is formed in rat tissues following 2-CAN 
administration. 
b. Determine whether the cytochrome P-450 inhibitor 5P1P administered prior to 2-
CAN, will reduce cyanate levels. 
c. Determine whether reduced cyanate levels are associated with a delay in the onset 
of hind-limb paralysis. 
  27 
3. Experimental Design 
To determine the effects of CYP inhibition, the following experimental design was used.  
All experiments using animals were conducted with standards consistent with the Animal 
Welfare Act and approved by the Institutional Animal Care and Use Committee of 
Duquesne University.  There were 4 groups of male Sprague-Dawley rats with 
approximately 10 animals per group. 
Figure 8 – Experimental Design 
 
4. Sample collection 
a. Tissue glutathione, blood cyanide, and plasma cyanate collection 
As described in Figure 8, male Sprague-Dawley rats were divided into four groups.  
The first group received vehicle (de-ionized water) at a dose of 1 mL per 100 g animal 
weight.  The second group received 40 mg/Kg 2-CAN.  The third group received 100 
mg/kg of 5-phenyl-1-pentyne (5P1P).  The fourth group received 100 mg/kg 5P1P 
followed one hour later with 40 mg/kg 2-CAN.  Dosages were administered i.p. between 
the hours of 8 and 10 AM.  This time range was selected because of the peak time of liver 
glutathione (GSH) diurnal rhythm.
95
  After 3 hours, the animals were anesthetized via 3% 
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isofluorane.  While under anesthesia, the abdomen was opened with scissors and the 
upper left lobe of the liver and the left lung were removed.  The tissues were rinsed with 
saline, cut into smaller pieces, and immediately placed in liquid nitrogen.  Blood was 
removed via cardiac puncture, placed in heparinized vials, and then placed on ice.  
Cardiac puncture was used to euthanize the animals.  One mL of whole blood was used 
for cyanide analysis and the remainder of the whole blood was centrifuged at 2,500 rpm 
for 20 minutes (Calculated G-force of 908 xG).  The supernatant (plasma) was 
immediately used for cyanate analysis. 
Based on the research of Mostowy
96
, 40 mg/kg 2-CAN was selected because of 
observed hind-limb paralysis and glutathione effects.  Liver and lung tissues were 
selected because glutathione levels were more sensitive to exposure to 2-CAN than heart 
and kidney.
96
  Previous studies showed that three hours was the time of maximum GSH 
depletion in the liver and nearly maximum GSH depletion in lung.
96
 
 5-phenyl-1-pentyne was selected as the cytochrome P-450 inhibitor because it 
inhibits both CYP2E1 and CYP2F2.  CYP2F2 is associated with metabolism in the lungs 
and MAN is excreted in the lungs at a higher rate than AN.  5P1P was also effective in 
reducing toxicity in styrene metabolism which is also dependent on lung metabolism. 
 
5. Tissue Glutathione, Blood Cyanide, and Plasma Cyanate Analysis 
 
a. Plasma Cyanate analysis.   
Plasma cyanate was determined using high performance liquid chromatography 
(HPLC) according to the method of Lundquist.
97
 The method involves the derivatization 
of cyanate with 2-aminobenzoic acid (figure 9) to form the stable fluorescent compound 
2,4(1H,3H)-Quinazolinedione.  One mL of the plasma supernatant was placed into a 
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glass test tube.  To the tube, 1 mL of 0.2 mL/l sodium phosphate buffer (pH 7.4) was 
added.  The pH of the solution was then adjusted to 4.7 by adding approximately 60 µL 
of 4 mol/L acetic acid.  2.1 mL of 40 mmol/l of 2-aminobenzoic acid (adjusted to pH 4.7 
with sodium acetate) was added and the entire solution mixed.  The tube was then 
incubated in 40°C water for 10 minutes.  The reaction was stopped by placing the tube in 
an ice bath.  A three mL aliquot was then placed into a new glass tube containing 3 mL of 
6 mol/L sulfuric acid.  This tube was then placed in a boiling water bath for 1 minute and 
15 seconds.  Again, the reaction was stopped by placing the tube into an ice bath.  The 
tube was then spun on a centrifuge at 2,000 rpm for 20 minutes.  Using a 10 mL syringe, 
the supernatant was then passed through a Minisart
®
 filter and placed into new tubes.  
Four mL was added to a new tube containing three mL of ethyl acetate.  The tube was 
capped and mixed for five minutes.  The tube was centrifuged for 10 min at 2,000 rpm.  
The organic phase was extracted and placed into a new glass test tube and three mL of 
ethyl acetate was added.  This process was repeated two more times, each time 
combining the organic phase into another tube.  The organic phase (which contained the 
sample) was then dried on a 40
o
 C heating block with dry nitrogen gas passing over the 
tubes.  The residue was then dissolved by adding a mixture of 2 mL of water and 60 µL 
of 5 mol/l HCl.  A 6 mL Mega Bond
®
 Elut column was then prepared by wetting with 3 
mL of water.  The sample was then added to the column and pushed through with 
nitrogen.  The effluent was collected.  The column was then washed twice with 2 mL of 
water with the effluent being collected each time.  To the combined effluent, 0.5 mL of 
0.1 mol/L sodium phosphate buffer (pH 7.4) was added.  The pH was then adjusted to 6-8 
by adding a few drops of three mol/L NaOH.  A Sep-Pak
®
 C-18 cartridge was then 
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prepared by washing with 3 mL of MeOH and then with three mL of water.  The sample 
was then added to the column and pushed through with nitrogen.  The column was then 
washed with three mL of water.  The effluent was not collected due to the fact that the 
derivatized sample was still on the column.  To extract the sample from the column, three 
mL of MeOH was added and pushed through with nitrogen.  The MeOH effluent was 
collected and dried.  The sample was then dissolved in 0.5 mL of mobile phase and 
analyzed by HPLC with fluorescence detection (excitation of 313nm and emission of 
353).  The quinazolinedione derivative was determined on the HPLC with a runtime of 
less than 30 minutes.  The quantification of cyanate in plasma was calculated based on a 
standard curve.  For standards, it was not necessary to centrifuge and filter prior to 
extraction with ethyl acetate. 
 
Figure 9 - Derivatization of cyanate for HPLC analysis 
 
See Appendix A for a description of the solutions used in cyanate analysis 
See Appendix B for the method to prepare the standard curve. 
See Appendix C for the method to analyze on a HPLC 
See Appendix D for the calculation to determine the cyanate concentration 
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b. Tissue Glutathione Analysis.  
 The glutathione level of each tissue was determined using the method of Farris 
and Reed High Performance Liquid Chromatography (HPLC).
98
 The tissue was removed 
from the liquid nitrogen, placed in the mortar and pestle that were cooled with liquid 
nitrogen.  The tissue was quickly ground, returned to the cryogenic container, and placed 
back into the liquid nitrogen.  This was done for each liver and lung sample. 
Nine hundred µL of the PCA/BPDS working solution was added to a 2 mL 
microcentrifuge tube.  The purpose of the PCA was to keep the GSH in its reduced form.  
BPDS acted as a metal chelator.  One hundred mL of the γ-Glu-Glu working solution was 
added as an internal standard.  The purpose of using the γ-glutamyl glutamate as the 
internal standard for both of the samples is to increase the accuracy of the method to 
greater than 95% for both the GSH and GSSG determinations.  The microcentrifuge tube 
containing the solution was then placed on a balance and net to zero.  Approximately 80-
100 mg of ground tissue was removed and placed in the tube.  The excess was wiped 
from the edges and the weight noted.  The tube was then sonicated on ice for 10 seconds 
and returned to the liquid nitrogen.  The samples were then allowed to thaw in 
refrigerator.  This took several hours.  The samples were each centrifuged at 13,000 X for 
10 minutes and 200 µL of the supernatant was removed and placed into a new 1.5 mL 
microcentrifuge tube. 
 To each of the supernatant samples, 50 µL of the IAA/m-cresol purple solution 
was added.  The samples were then adjusted to have a pH of 8-9 by using KOH/KHCO3 
Solution.  The KOH/KHCO3 solution was added at no more than 50 µL increments to 
prevent the sample from bubbling over.  A total of 130 µL was added to each sample. 
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The samples were then covered in a thick black cloth and put into a laboratory drawer for 
one hour.  The purpose of this step was for the iodoacetic acid to react with the thiols in 
order to form S-carboxymethyl derivatives.  The purpose of the m-cresol purple was not 
only to function as a pH indicator, but also as a preservative.   
 The reaction of the iodoacetic acid with the thiols and forming S-carboxymethyl 
derivatives of thiols eliminated the potential for thiol disulfide interchange.  An equal 
volume of FDNB solution was added to each sample (380 µL).  Samples were then 
incubated in a dark environment at room temperature for 18-24 hours.  The tubes were 
covered by a thick black cloth and put into a lab drawer in order to keep the samples in 
complete darkness.  After 24 hours in room temperature darkness, the samples were 
placed in a 13,000 X centrifuge for 20 minutes.  One hundred µL of the supernatant was 
added to the autosampler tubes and placed into the autosampler.  In addition to samples, a 
standard curve, GSH only, and GSSG only samples were analyzed via HPLC with 
UV/Vis detection at a wavelength of 365nm.  Each run took about 45 minutes.  Using the 
standard curve, the concentrations of GSH and GSSG were calculated for each sample.   
 Appendix E is a description of the working solutions used during the glutathione 
analysis. 
 Appendix F is a description of the method used to prepare GSH and GSSG 
standards. 
 Appendix G is a description of solvent and gradient system used during the 
glutathione analysis. 
 Appendix H is a description of the calculations used to determine the levels of 
GSH and GSSG. 
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 Appendix I is a description of column and HPLC retention times. 
Appendix J is representative HPLC chromatographs and standard curves. 
 
c.     Blood Cyanide Analysis.  
Whole Blood – Following anesthesia with Isoflurane, a 10 mL syringe with a 20 G needle 
was used to extract whole blood from the heart of the animal.  For most animals, this 
quantity was 7-9 mL.  The whole blood was then added to a heparinized vial and placed 
on ice.  The whole blood was then analyzed for cyanide by a method similar to that of 
Feldstein and Klendshoj.
99
  
 The method utilizes a procedure of microdiffusion in which cyanide is liberated as 
hydrogen cyanide from blood.  A Conway microdiffusion dish was used for this method.  
This is a flat circular dish with two circular walls dividing the dish into three wells 
referenced as the outer well, the middle, and the center well.  The inner well is slightly 
shorter than the outer well to allow chemicals to be separated.  There is a lid that fits into 
the outer well.  It is used to prevent the release of gases. 
The general principle of the analysis is mixing blood with sulfuric acid to release 
hydrogen cyanide gas (HCN).  The cyanide gas will then be absorbed by the sodium 
hydroxide in the center well.  Diffusion typically takes 2-4 hours at room temperature.  
The HCN will then be converted to cyanogens chloride by treating the sodium 
hydroxide/cyanide solution with chloramine T and reacting the cyanogens chloride with 
pyridine and barbituric acid (2,4,6-trioxohexahydropyremidine) resulting in the formation 
of a blue dye.  The dye is then quantitated by spectrophotometry.  The specific procedure 
to this method is as follows: 
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 To seal the lid onto the Conway diffusion dish, 1 mL of 0.2 N H2SO4 was added 
to the outer well.  One mL of whole blood containing heparin was added to one side of 
the middle well of the dish.  0.5 mL of 10% H2SO4 was added to the other side of the 
middle well, ensuring that reagents did not come into contact with one another.  0.2 mL 
of 0.1 NaOH was added to the center well.  The lid was then applied, rotated and lifted 
slightly to confirm a tight seal.  The plate was then swirled slightly to ensure the sulfuric 
acid solution mixed well with the heparinized blood, and allowed to diffuse at room 
temperature for 3 hours. 
 Once diffusion was concluded, the contents of the center well were transferred to 
a 5 mL volumetric flask.  The center well was rinsed twice with 0.25 mL of sodium 
hydrogen phosphate reagent and added both times to the same volumetric flask.  A 
volume of 0.25 mL of chloramine T reagent was then added to the flask and mixed.  This 
solution was allowed to sit for three minutes.  A volume of 0.1 mL of barbituric acid 
reagent was added to the flask, mixed, and allowed to stand for five minutes.  Deionized 
water was then added to the flask to bring the total volume to five mL.  The absorbance 
was then measured using an ultraviolet spectrophotometer at a wavelength of 580 nm.  
The concentrations of the standards were 0.01 µg/mL, 0.1 µg/mL, 0.2 µg/mL, and 0.5 
µg/mL.  A blank was also run.   
See Appendix K for description of the working solutions used in the blood cyanide 
analysis. 
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6. Measurement of hind-limb paralysis 
Male Sprague-Dawley rats were randomly divided into 2 groups and weighed (350-
550g).  The first group (n=5) was dosed via i.p. injections with 40 mg/kg of 2-CAN.  The 
second group (n=5) was administered 100 mg/kg of 5P1P, i.p. 1 hour prior to receiving 
40 mg/kg of 2-CAN via i.p injection.  Immediately after dosing with 2-CAN, the animal 
was returned to the plastic cage and a timer was started.  The animal was then observed 
for the first onset of hind-limb paralysis.  Normally a rat would move its front limbs in 
combination with its hind limbs.  With 2-CAN induced hind limb paralysis, the animal 
will move its front limbs but not immediately move the rear.  The animal then 
experiences an unnatural extension of the hind legs.  This was noted as the time of onset 
of hind-limb paralysis.  There were also treatment groups for vehicle and 5P1P alone for 
a physiological baseline.   
Figure 10 – Experimental Design for hind-limb paralysis  
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7. Statistical Analysis 
Values are expressed as mean ± S.E.M..  For glutathione, cyanide, and cyanate analysis, a 
one-way analysis of variation (ANOVA) was performed followed by a Newman-Keuls’ 
multiple comparison test post-hoc.  For the onset of hind-limb paralysis, a t-test was 
utilized.  For all results, a “p-value” of less than 0.05 was considered significant.  
GraphPad Prism 5.03 (GraphPad Software Inc.) was the software program used.  
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III. Results and Discussion 
A. Results 
To test the hypothesis that 2-CAN toxicity is associated with cyanate formation 
and whether a CYP inhibitor (5P1P) would provide a protective mechanism, male 
Sprague-Dawley rats were injected i.p. with vehicle (deionized water), 2-CAN (40 
mg/kg), 5P1P, or 5P1P followed by 2-CAN as described in the Methodology and 
Procedures section.  In a second experiment, male Sprague-Dawley rats were injected i.p. 
with 2-CAN (40 mg/kg) or 5P1P (100 mg/kg) followed by 2-CAN as described. 
 
1. Gross animal observations 
In the control and 5P1P treated animals, there were no unusual observations.  In 2-
CAN treated animals, immediately following injection they displayed piloerection.  
Within 5 minutes there was reduced movement, eye closing, and shallow breathing.  Hind 
limb paralysis was noted around this same time.  When the abdomen was opened to 
remove the liver and lungs, there was an excessive amount of fluid in the peritoneal 
cavity.  Lungs were a coral color and the stomach and intestines were enlarged.  The 
group of animals that received 5P1P prior to 2-CAN had many of the same gross effects 
as 2-CAN, but was observed to be at a lesser extent.  These animals had some reduction 
in movement, some eye closing, and less pronounced shallow breathing.  Hind limb 
paralysis was also observed but the effects were not as dramatic.  There was some fluid in 
the peritoneal cavity.  Lungs were a coral color and the stomach and intestines were 
slightly enlarged. 
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2. Tissue GSH levels. 
Previous work from Mostowy showed that 40 mg/kg of 2-CAN (i.p.) will deplete 
lung glutathione level by 31% after 3 hours.  In addition to repeating the work by 
Mostowy, this study will determine the effect of a CYP inhibitor (5P1P) administered 1 
hour prior to 2-CAN.  It is expected the animals administered 5P1P prior to 2-CAN 
would have more GSH depletion compared to 2-CAN alone because the toxic metabolic 
pathway would shift from oxidation (via CYP) to conjugation with GSH.  Figure 11 
shows the effects of 2-CAN on GSH levels in lung with and without 5P1P.  There was no 
change in the vehicle compared to the 5P1P only group.  The decrease in GSH in the 2-
CAN group and the 5P1P + 2-CAN group were both statistically significant compared to 
vehicle.  For the 2-CAN group, the lung GSH concentrations decreased from 1866 
µmol/g tissue to 1480 µmol/g tissue; a decrease of about 20%.  For the 5P1P + 2-CAN 
group the lung GSH concentration decreased from 1866 µmol/g tissue to 1432 µmol/g 
tissue.  This is a decrease of approximately 23%.  There was no significant different 
between the GSH concentrations in the 2-CAN group and the CYP + 2-CAN group. 
 
Previous work from Mostowy showed little increase in lung GSSG levels after 40 
mg/kg 2-CAN administration (i.p.)  It would be expected that 5P1P administered prior to 
2-CAN would not significantly increase GSSG concentrations because on the proposed 
toxic mechanism, very little GSH is oxidized to GSSG and inhibition of CYP would not 
be expected to change this.  Figure 12 shows the effect of 2-CAN on the GSSG levels in 
the lung with and without 5P1P.  There was not a statistically significant increase in 
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GSSG concentrations in the 5P1P and 5P1P + 2-CAN groups compared to vehicle and 2-
CAN.The concentration of GSH in the rat lung was many times greater than the 
concentration of GSSG.  To illustrate this, Figure 13 shows the relative quantity of lung 
GSH compared to GSSG in the different groups.   
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Figure 11. The effect of 2-CAN and 5P1P on lung GSH levels  
 
 
Figure 11.  Comparison of GSH levels in the lungs of rats administered vehicle (i.p.); 2-
CAN (40 mg/kg i.p); a CYP inhibitor (5P1P); or a CYP inhibitor (5P1P) 1 hour prior to 
2-CAN (40 mg/kg i.p).  Tissue was removed 3 hours after the last injection.  Each bar 
graph represents the mean ± SEM of 9-12 animals performed in duplicate.  Data were 
analyzed by 1-way ANOVA followed by a Newman-Keuls’ post-hoc test where (*) 
significance indicates p<0.05 
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Figure 12. The effect of 2-CAN and 5P1P on lung GSSG levels 
 
 
Figure 12.  Comparison of GSSG levels in the lungs of rats administered vehicle (i.p.); 2-
CAN (40 mg/kg i.p); a CYP inhibitor (5P1P); or a CYP inhibitor (5P1P) 1 hour prior to 
2-CAN (40 mg/kg i.p).  Tissue was removed 3 hours after the last injection.  Each bar 
graph represents the mean ± SEM of 7-11 animals performed in duplicate.  Data were 
analyzed by 1-way ANOVA followed by a Newman-Keuls’ post-hoc test.  There was no 
statically significant change between any of the groups. 
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Figure 13. Relative amounts of GSH and GSSG levels in the lung following 2-CAN and 
5P1P administration  
 
 
Figure 13.  Relative amounts of GSH and GSSG in the lungs of rats administered 
vehicle (i.p.); 2-CAN (40 mg/kg i.p); a CYP inhibitor (5P1P); or a CYP inhibitor (5P1P) 
1 hour prior to 2-CAN (40 mg/kg i.p).  Tissue was removed 3 hours after the last 
injection.  Each bar graph represents the mean ± SEM of 7-12 animals performed in 
duplicate.  Data were analyzed by 1-way ANOVA followed by a Newman-Keuls’ post-
hoc test where significance (*) indicates p<0.05
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Previous work from Mostowy showed that 40 mg/kg of 2-CAN (i.p.) will deplete liver 
glutathione level by 42% after 3 hours.  In addition to repeating the work by Mostowy, 
this study will determine the effect of a CYP inhibitor (5P1P) administered 1 hour prior 
to 2-CAN.  It is expected the animals administered 5P1P prior to 2-CAN would have 
more GSH depletion compared to 2-CAN alone because the toxic metabolic pathway 
would shift from oxidation (via CYP) to conjugation with GSH.  Figure 14 shows the 
effect of 2-CAN on the GSH levels in the liver with and without 5P1P.  There was no 
change in vehicle control group compared to the 5P1P only group.  The decrease in the 2-
CAN group and the 5P1P + 2-CAN group were both statistically significant compared to 
vehicle.  For the 2-CAN group, the liver GSH concentration decreased from 6989 µmol/g 
tissue to 3913 µmol/g tissue.  This is a decrease of approximately 44%.  For the 5P1P + 
2-CAN group the lung GSH concentration decreased from 6989 µmol/g tissue to 3524 
µmol/g tissue.  This is a decrease of approximately 50%.  There was no significant 
different between the GSH concentration in the 2-CAN group and the 5P1P + 2-CAN 
group. 
Previous work from Mostowy showed little increase in liver GSSG levels after 40 
mg/kg 2-CAN administration (i.p.)  It would be expected that 5P1P administered prior to 
2-CAN would not significantly increase GSSG concentrations because on the proposed 
toxic mechanism, very little GSH is oxidized to GSSG and inhibition of CYP would not 
be expected to change this.  Figure 15 shows the effect of 2-CAN on the GSSG levels in 
the liver with and without 5P1P CYP inhibitor.  Although there appears to be an increase 
in GSSG concentrations in the 2-CAN group compared to vehicle, CYP, and CYP + 2-
CAN, the increase was not statistically significant. 
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The concentration of GSH in the rat lung was many times greater than the 
concentration of GSSG.  To illustrate this, Figure 16 shows the relative quantity of liver 
GSH compared to GSSG in the different groups.  The quantity of GSSG compared to 
GSH is vastly different. 
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Figure 14. The effect of 2-CAN and 5P1P on liver GSH levels 
 
 
Figure 14.  Comparison of GSH levels in the liver of rats administered vehicle (i.p.); 2-
CAN (40 mg/kg i.p); a CYP inhibitor (5P1P); or a CYP inhibitor (5P1P) 1 hour prior to 
2-CAN (40 mg/kg i.p).  Tissue was removed 3 hours after the last injection.  Each bar 
graph represents the mean ± SEM of 9-11 animals performed in duplicate.  Data were 
analyzed by 1-way ANOVA followed by a Newman-Keuls’ post-hoc test where 
significance (*) indicates p<0.05 
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Figure 15. The effect of 2-CAN and 5P1P on liver GSSG levels 
 
 
Figure 15.  Comparison of GSSG levels in the liver of rats administered vehicle (i.p.); 2-
CAN (40 mg/kg i.p); a CYP inhibitor (5P1P); or a CYP inhibitor (5P1P) 1 hour prior to 
2-CAN (40 mg/kg i.p).  Tissue was removed 3 hours after the last injection.  Each bar 
graph represents the mean ± SEM of 8-10 animals performed in duplicate.  Data were 
analyzed by 1-way ANOVA followed by a Newman-Keuls’ post-hoc test.  There was no 
statically significant change between any of the groups.    
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Figure 16. Relative amounts of GSH and GSSG levels in the liver following 2-CAN and 
5P1P administration 
 
 
Figure 16.  Relative amounts of GSH and GSSG in the liver of rats administered vehicle 
(i.p.); 2-CAN (40 mg/kg i.p); a CYP inhibitor (5P1P); or a CYP inhibitor (5P1P) 1 hour 
prior to 2-CAN (40 mg/kg i.p).  Tissue was removed 3 hours after the last injection.  Each 
bar graph represents the mean ± SEM of 8-11 animals performed in duplicate.  Data were 
analyzed by 1-way ANOVA followed by a Newman-Keuls’ post-hoc test where 
significance (*) indicates p<0.05 
* p<0.05; n=8-11 
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 Previous work from Mostowy showed that 40 mg/kg of 2-CAN (i.p.) will increase 
blood cyanide levels, but well below the level known to produce adverse effects.  In 
addition to repeating the work by Mostowy, this study will determine the effect of a CYP 
inhibitor (5P1P) administered 1 hour prior to 2-CAN.  It is expected the animals 
administered 5P1P prior to 2-CAN would have a reduction in cyanide levels.  Based on 
the proposed toxic metabolic pathway for 2-CAN, cyanide can only be formed after 
oxidation by CYP2E1.  A CYP inhibitor would reduce the amount of oxidation and 
therefore the amount of cyanide formed.  Figure 17 shows the effect of 2-CAN on the 
blood cyanide levels with and without the CYP inhibitor 5P1P.  The blood cyanide 
concentration in the 2-CAN group was significantly increased compared to vehicle.  
Although there appears to be an increase in blood cyanide levels in the 5P1P + 2-CAN 
group, the increase was not statistically significant compared to the vehicle group. 
Due to a lack of cyanide formation, the hypothesis of this dissertation is that the 
cyanide may be oxidized to cyanate.  In addition to determining if cyanate is formed 
following 2-CAN administration, a CYP inhibitor (5P1P) would decrease the amount of 
oxidation.  According to the proposed toxic mechanism for 2-CAN, cyanide and cyanate 
are only formed after oxidation of 2-CAN.  Therefore it would be expected that 5P1P 
administered prior to 2-CAN would decrease the concentration of plasma cyanate.  
Figure 18 shows the effect of 2-CAN on the plasma cyanate levels with and without the 
CYP inhibitor 5P1P.  The plasma cyanate concentration in the 2-CAN group was 
significantly increased compared to vehicle.  For the 2-CAN group, the plasma cyanate 
concentration increased from 88.9 nmol/L plasma to 435 nmol/L plasma; this is an 
increase of about 390%.  In the group that received 5P1P 1 hour prior to 2-CAN 
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administration, the plasma cyanate concentration was significantly less than the animals 
that received 2-CAN alone.  For the 5P1P + 2-CAN group, the plasma cyanate 
concentration decreased from 435 nmol/L plasma to 194.4 nmol/L plasma;  this was a 
decrease of 55%.  The increase in cyanate levels in the 5P1P + 2-CAN group was not 
statistically significant compared to the vehicle or CYP groups. 
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Figure 17. The effect of 2-CAN and 5P1P on blood cyanide levels 
 
 
Figure 17.  Comparison of blood cyanide levels rats administered vehicle (i.p.); 2-CAN 
(40 mg/kg i.p); a CYP inhibitor (5P1P); or a CYP inhibitor (5P1P) 1 hour prior to 2-CAN 
(40 mg/kg i.p).  Tissue was removed 3 hours after the last injection.  Each bar graph 
represents the mean ± SEM of 6-7 animals.  Data were analyzed by 1-way ANOVA 
followed by a Newman-Keuls’ post-hoc test where significance (*) indicates p<0.05 
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Figure 18. The effect of 2-CAN and 5P1P on plasma cyanate levels 
 
 
Figure 18.  Comparison of plasma cyanate levels rats administered vehicle (i.p.); 2-CAN 
(40 mg/kg i.p); a CYP inhibitor (5P1P); or a CYP inhibitor (5P1P) 1 hour prior to 2-CAN 
(40 mg/kg i.p).  Tissue was removed 3 hours after the last injection.  Each bar graph 
represents the mean ± SEM of 9-11 animals.  Data were analyzed by 1-way ANOVA 
followed by a Newman-Keuls’ post-hoc test where significance (*) indicates p<0.05 
 
 
  52 
There is only limited information in the literature associating plasma cyanate 
concentrations and hind-limb paralysis.  To determine if the changes observed with 
plasma cyanate levels are biologically relevant, Figure 19 shows the effect of 2-CAN on 
the time to onset of hind-limb paralysis compared to animals that received 5P1P 1 hour 
prior to 2-CAN.   The time to onset of hind-limb paralysis was significantly increased 
when 5P1P was administered prior to 2-CAN.  The time to onset increased from 6.4 
minutes to 16 minutes.  This is an increase of 150%.   
Figure 19. Time to onset of hind-limb paralysis following 2-CAN and 5P1P 
administration 
 
Figure 19.  
Comparison of time to onset of hind-limb paralysis in rats administered 2-CAN (40 
mg/kg i.p) or a CYP inhibitor (5P1P) 1 hour prior to 2-CAN (40 mg/kg i.p).  Shown is a 
scatter plot of the data where the horizontal line between the points represents the mean  
data for 5 animals.  Each data point (triangles) represents the time for each individual 
animal.  Data were analyzed by an unpaired t-test where significance (*) indicates 
p<0.005 
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Discussion 
The results of this research support the hypothesis that cyanate, not cyanide, is the 
toxic endpoint for the metabolism of 2-CAN.  Three hours after administration of 40 
mg/kg 2-CAN, there was a 390% increase in plasma cyanate levels.  Blood cyanide levels 
did increase, but 0.06 µg/L is well below the level known to produce adverse effects.  
Cyanate is known to cause hind-limb paralysis, but there is little information in the 
literature if the plasma levels seen following 2-CAN administration (435 nmol/L) are 
sufficient to induce hind-limb paralysis. 
Acrylonitrile (AN) depletes glutathione to a significantly greater extent than 2-
chloroacrylonitrile (2-CAN).
100
  For example, the LD50 for AN is (80 mg/kg (s.c.), and 
liver GSH levels are decreased by more than 90%.
100
  With 2-CAN, the decrease in liver 
GSH was less than 50%.  This indicates that although glutathione depletion is significant, 
it does not deplete the cells to a point where 2-CAN is covalently binding to tissue 
protein as observed with AN.  It is more likely that 2-CAN is being converted to the 
epoxide via cytochrome p-450 enzymes or being exhaled unchanged. 
Unlike AN which dramatically depletes liver GSH levels, 2-CAN is similar to 
MAN and only depletes liver GSH by less than 50%.  One explanation is that AN is 
being conjugated and ultimately excreted in the urine via the mercapturic acid pathway.  
2-CAN might be metabolized via cytochrome p-450 enzymes or pass through the liver 
unmetabolized.  This pathway is known to occur for MAN which is exhaled 
unmetabolized in the lungs to a much larger extent then AN.
21
  The increased GSH 
depletion observed with AN could be due its increased reactivity compared to MAN.
100
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Based on the proposed toxic mechanism, cytochrome p-450 activation to the 
epoxide is needed to form cyanide.  If MAN and 2-CAN are excreted unmetabolized, this 
would explain why they produce less cyanide.  Comparing the levels of cyanide formed 
by AN, MAN, and 2-CAN (Table 3) to Table 2, the cyanide levels observed following 2-
CAN administration are not high enough to be a cause of lethality.  One explanation 
might be the conversion of cyanide to cyanate. 
 
Table 3 – Relative effects of nitrile compounds on GSH depletion and cyanide formation 
in male Sprague Dawley rats 
Chemical LD50 Dose Route Time 
Liver GSH 
depletion 
 (% decrease) 
Blood Cyanide 
Level 
AN 
80 
mg/kg 
50 
mg/kg s.c. 1 hour 85%
100
 70 nmol/mL
100
 
AN 
80 
mg/kg 
80 
mg/kg s.c. 2 hour 92%
100
 140 nmol/mL
100
 
AN 
80 
mg/kg 
115 
mg/kg s.c. 2 hour 93%
100
 160 nmol/mL
100
 
MAN 
200 
mg/kg 
100 
mg/kg oral   39%
101
 Not Detectable
46
 
2-CAN 
20 
mg/kg 
40 
mg/kg i.p. 3 hour 44% 2 nmol/mL 
 
 
 After exposure of the rats to 2-CAN, there was a significant decrease in liver and 
lung GSH levels after 3 hours.  When the animals were pre-treated with 5P1P before 2-
CAN exposure, this did not change the GSH depletion.  Based on chemical structure and 
lack of an increase in GSSG levels, it is probable that GSH is directly conjugating with 2-
CAN or a 2-CAN epoxide. 
  55 
 Based on the proposed mechanism of 2-CAN (Figure 20), it might be expected 
that 5P1P might cause more GSH depletion by blocking the CYP pathway.  The results 
did not show a change in GSH or GSSG levels after pretreatment with 5P1P.  One 
explanation is that if the glutathione conjugation pathway is saturated and if the CYP 
pathway is blocked, more 2-CAN will be exhaled unreacted.   
 N-acetylcysteine (NAC) has been shown to reduce that toxicity of AN in rats by 
reducing the amount cyanide formed and increasing the LD50.
27
  This was thought to 
happen by providing the sulfur source for the rate limiting step in glutathione synthesis.  
As described in Figure 4., cyanide (CN) is normally metabolized to thiocyanate (SCN
-
) 
via the sulfur-dependent enzyme rhodanese and then excreted in the urine.
27
  It may also 
provide a sulfur source for rhodanese to convert cyanide to thiocyanate for normal 
metabolism and prevent the formation of cyanate.   
Based on the data obtained, it appears some 2-CAN is metabolized by direct 
conjugation with GSH, but a portion of 2-CAN is also oxidized to the epoxide.  The 
epoxide can then be metabolized by epoxide hydrolase (EH), reduced, or the epoxide can 
be conjugated with GSH.  Both the EH and reduction pathways could lead to cyanide 
formation, which was the original hypothesis for the toxic endpoint of 2-CAN.  
Unfortunately the data generated by this dissertation indicates that free cyanide is not 
found in the blood.  Though blood cyanide levels were increased in the 2-CAN group, 
levels did not exceed 0.06 µg/mL, which is a concentration well below the minimum for 
producing any adverse health effects. (Refer to Table 2) 
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Figure 20 – 3D structure and electron space filling model of GSH and AN 
 
As illustrated by the red arrow in Figure 20, the sulfhydryl group of glutathione 
must bind with the electron donating position on the nitrile compound.   
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Figure 21 – Comparison of predicted steric hindrance potential of AN, MAN, and 
2-CAN 
 
As illustrated in Figure 21, MAN has more steric hindrance compared to AN.  2-
CAN has even more steric hindrance.  The larger the compound, the least likely it will be 
able to bind with GSH.  Based on this model, AN is predicted to the most reactive with 
GSH, followed by MAN, and 2-CAN would be the least reactive. 
 
  58 
Figure 22 – Predicted electron donor potential of AN, MAN, and 2-CAN 
 
In addition to physically binding to GSH, the compound must also accept an electron.  
The larger the partial positive change at the binding site, the more likely it will accept the 
electron.  In the case of AN, MAN, and 2-CAN, all have the same cyanide group creating 
a partial positive charge.  With the addition of the methyl group on MAN, this pulls 
electrons toward the center of the compound and decreases the partial positive charge.  
The chlorine group on 2-CAN has the opposite effect of MAN and pulls electrons away 
from the center of the compound and increases the partial positive charge.  Based on 
electron donating potential, it is predicted that 2-CAN would be the most reactive, 
followed by AN, and MAN would be the least reactive.     
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Table 4 – Comparison of predicted electron donor and steric hindrance with actual GSH 
depletion data. 
 
Compound  Electron 
Donor  
Steric 
Hindrance  
Rat Liver 
GSH depletion  
AN  Intermediate  Least  85% 
100
 
MAN  Least Reactive  Intermediate  39%
102
 
2-CAN  Most Reactive  Greatest  44%  
 
Based on the predicted electron donating potential of AN, MAN, and 2-CAN, it 
would be expected that 2-CAN would be the most reactive and have the greatest GSH 
depletion.  This does not agree with the actual results which indicate that 2-CAN and 
MAN only have about one half of the amount of GSH depletion that is seen in AN.  
Based on the predicted steric hindrance, AN has the least steric hindrance and therefore 
would be most likely to bind and deplete GSH.  This agrees with the results seen in rat 
experiments.  Based on this information, steric hindrance is a better predictor of GSH 
depletion potential than electron donating potential.  This would explain why GSH 
depletion in 2-CAN is not nearly to the extent seen in AN. 
 As described in Figure 4, normally when cyanide is formed in a tissue, it is 
reacted with a sulfur donor to form thiocyanate and excreted in the urine.  It is known that 
the conversion of acrylonitrile to cyanide is saturable.
39
  The conversion of cyanide to 
cyanate only happens after the thiocyanate pathway is saturated.
53
  
If conversion of cyanide to cyanate needs a sulfur depleted system, why do we not 
see this effect in AN which cause greater GSH depletion?  The answer has to do with the 
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target organ.  An adverse effect associated with both cyanate and 2-CAN is hind-limb 
paralysis.  This is most likely an effect on the nervous system.  For example, although 
AN depletes GSH in the liver by 90%
100
, it only depletes GSH in the brain by 40%.
103
    
If 2-CAN causes glutathione depletion in the brain and/or spinal cord, the cyanide to 
cyanate oxidation could take place in these organs.  
To test the hypothesis that a CYP inhibitor would prevent cyanate formation, 
5P1P was administered 1 hour prior to 2-CAN.  The inhibitor significantly reduced 
cyanate formation by 55%.  To further confirm that cyanate formed by 2-CAN is 
associated with the hind-limb paralysis, the time to onset was measured in the 2-CAN vs. 
5P1P prior to 2-CAN.  The time to onset was delayed from 6 to 16 minutes. Early 
theories indicated that cyanate hind-limb paralysis was a function of demyelization.  
More recent studies indicate cyanate can quickly cause hind-limb paralysis by interfering 
with the function of potassium channels in neurons.
68
  Increasing the opening of these 
channels would result in a decrease in neuronal excitability. 
Summary 2-CAN mechanism of action: 
The original theory proposed by the manufacturer of 2-CAN is that 2-CAN 
caused cyanide toxicity in animals and humans.  This was disproved by Mostowy in 2000 
who demonstrated that GSH depletion was most dramatic in rat liver and kidney.  The 
largest decrease was observed at 3 hours after injection of 2-CAN at 40 mg/kg. (i.p.).  
Cyanide levels observed were sub-clinical. 
The current research finds that cyanate formation, not cyanide is the major toxic 
metabolite.  5P1P reduced the quantity of cyanate formation.  Cyanate levels were 
biologically relevant because the cyanate decreased by 5P1P caused a delay in the onset 
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of hind-limb paralysis.  However, 5P1P administration did not significantly alter 
glutathione levels. 
Based on the results of this research, Figure 20 describes the proposed mechanism 
of 2-CAN.  The key difference from MAN and AN is the conversion of cyanide to 
cyanate.  This is due to the depletion of sulfur sources as indicated by the reduction in 
glutathione. 
The kinetics of 2-CAN is not known.  When CYP2E1 knockout mice were 
administered MAN orally, the amount of radiolabeled CO2 (a metabolite of the epoxide 
formed from cytochrome p-450s) decreased 3-5 fold compared to wild-type.
48
  When 
cyanide was administered orally to rats on a sulfur deficient diet, the plasma cyanate level 
was 4 fold higher than control animals.
53
 
2-CAN was shown to deplete glutathione.  Glutathione synthesis is rate limited by 
sulfur availability.  Therefore, it would be expected that cells would be deficient in sulfur.  
Glutathione depleted cells have less capacity to reduce free radicals.  When cyanide is 
formed following CYP activation to epoxide, it is expected there would not be a sulfur 
source for normal rhodanese detoxification of cyanide because it requires a sulfur source.  
In combination with decreased glutathione for reduction, it expected that cyanide would 
be oxidized to cyanate. 
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Figure 23 – Proposed Mechanism of 2-CAN    
 
Significance of this research 
 The current research showed for the first time that 2-CAN administration could 
cause cyanate formation.  With additional testing in rats or possibly humans, suppliers of 
2-CAN may be able to remove any recommendation for treatment associated with 
cyanide toxicity and instead focus on treatment for cyanate toxicity.  For example, 
immediately after exposure a person could be given an antidote to enhance glutathione 
levels, presumably in the brain or CNS. Often this will be a compound such as NAC.  In 
addition to acting as a precursor to GSH synthesis, it would act as a sulfur source for 
rhodanese to convert cyanide to thiocyanate.  
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Conclusion 
 The results of this research support the hypothesis that acute exposure to 2-CAN 
causes glutathione depletion, minimal cyanide formation, and cyanate formation.  Pre-
treatment with a CYP2E1 inhibitor, 5P1P, significantly reduced cyanate formation and 
the time to onset of hind-limb paralysis. 
 Blood cyanide levels 3 hours after exposure were too low to cause a toxic effect.  
When the animals were pre-treated with 5P1P before 2-CAN exposure, there was no 
change in the trace amount of cyanide formed.  This result indicates that with or without 
a CYP450 inhibitor, cyanide levels were not biologically significant. 
 Plasma cyanate levels 3 hours after exposure were significantly increased in the 2-
CAN exposed group.  When administered 5P1P prior to 2-CAN exposure, the amount of 
cyanate formed was reduced by more than 50%. 
 Acute onset hind-limb paralysis was observed with animals following 2-CAN 
exposure.  The time to onset of hind limb paralysis was measured in the 2-CAN group 
and animals that received the CYP inhibitor 5PS1P prior to 2-CAN.  It took the inhibitor 
group an average of 16 minutes to have the first signs of hind-limb paralysis.  This is a 
significantly longer period of time compared to an average of 6 minutes for the 2-CAN 
only group. 
 The data in this research indicate that cyanide formation is not the primary toxic 
intermediate formed from 2-CAN exposure but suggests that cyanate formation plays a 
significant role in the neurological effect observed with hind limb paralysis.  A CYP 
inhibitor administered prior to 2-CAN exposure can reduce cyanate formation and delay 
the onset of hind-limb paralysis. 
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V. Appendices 
 
Appendix A 
 
1. Solutions for cyanate analysis 
Cyanate Stock Solution (5 µmol/l) 
 
Dissolve 81.12 mg potassium cyanate in 1 L of de-ionized water to create 1 mM 
solution.  Mix completely.  Remove 0.5 mL of this solution (1 mM) and bring to a 
total volume of 100 mL with de-ionized water. 
 
The shelf life of this solution is short and must be created at the beginning of each 
experiment. 
 
0.2 mol/L sodium phosphate buffer (pH 7.4) 
 
Create a 1M Sodium Phosphate Monobasic solution by dissolving 12g of sodium 
phosphate monobasic in 100 mL of water. 
 
Create a 1M Sodium Phosphate Dibasic solution by dissolving 14.2g of sodium 
phosphate dibasic in 100 mL of water. 
 
Combine 77.4mL of 1M sodium phosphate dibasic and 22.6mL of 1M sodium 
phosphate monobasic and bring the total volume to 500mL by adding de-ionized 
water. 
 
4 mol/L acetic acid 
 
Acetic acid is used to adjust the pH to 4.7.  This is critical to ensure the proper 
derivative is formed (See Figure 9) 
 
Add 77mL of de-ionized water to a 100mL graduated cylinder.  Add 23mL of 
glacial acetic acid for a total volume of 100mL. 
 
40 mmol/L 2-aminobenzoic acid (adjusted to pH 4.7) 
 
2-aminobenzoic acid reacts with cyanate to form 2-ureidobenzoic acid, the first 
reaction step in the derivativation process. 
 
Dissolve 556 mg of Anthranilic Acid (2-aminobenzoic acid) in 100 mL of de-
ionized water.  Place solution in flask with mixing rod.  While mixing, enter the 
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probe for the pH meter and slowly add small amounts of sodium acetate until the 
pH has been adjusted to 4.7. 
 
The shelf life of this solution is short and must be created at the beginning of each 
experiment. 
 
 
6 mol/L sulfuric acid 
 
Sulfuric acid is used to react 2-ureidobenzoic acid to 2,4-quinazolinedione which 
is ultimately measured in the fluorescence detector.   
 
Add 66.6mL of de-ionized water to a 100mL graduated cylinder.  Add 33.3mL of 
concentrated sulfuric acid (18M) for a total volume of 100mL. 
 
5 mol/L Hydrochloric acid 
 
 Hydrochloric acid is used to adjust pH. 
 
Add 57mL of de-ionized water to a 100mL graduated cylinder.  Add 43 mL of 
concentrated HCl (11.6M) for a total volume of 100mL. 
 
3 mol/L Sodium Hydroxide 
 
 Sodium hydroxide is used to adjust pH. 
 
Add 70mL of de-ionized water to a 100mL graduated cylinder.  Add 30mL of 
10M Sodium Hydroxide solution for a total volume of 100mL. 
 
HPLC Mobile Phase for cyanate analysis 
 
Methanol is filtered using a 0.45uM Millipore filter attached to a vacuum flask. 
 
HPLC-grade water is filtered using a 0.45uM Millipore filter attached to a 
vacuum flask. 
 
It is critical to filter all reagents for mobile phase and use HPLC-grade water to 
prevent the column from clogging. 
 
1 L of the filtered methanol is then added to 2 L of the filtered water 
  66 
Appendix B 
 
1. Method to prepare the standard curve. 
 
The day of each new experiment, a standard curve was run in parallel to the animal 
sample.  Glass test tubes were labeled and a known amount of the potassium cyanate 
stock solution was added to each tube.  De-ionized water was then added to bring the 
total volume in each tube to 1 mL. 
 
Volume of cyanate stock 
solution added to tube 
Total Concentration in tube 
0 µL Blank 
10 µL 50 nM 
30 µL 150 nM 
60 µL 300 nM 
100 µL 500 nM 
 
After the same procedure is followed as with the plasma (with the exception of the 
Minisart filter) the standard is run through the HPLC with fluorescence detection and the 
area under the curve (AUC) is recorded and plotted against the known concentrations in 
each of the tubes.  Listed below is an example standard curve. 
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Appendix C 
 
1. Method to analyze on a HPLC  
 
Autosampler 
 
The dried sample is dissolved in 0.5mL of cyanate mobile phase and then added 
to the HPLC autosampler vial.  After being capped, it is loaded into the 
autosampler. 
 
HPLC setup 
 
The cyanate prefilter (Kromasil C-18 (5µm, 10x3.2 mm); Hicrome Ltd) was 
added in line prior to the cyanate column (Kromasil KR 100-5C-18 (5µm 
250x4.6mm); Hircrom Ltd)  .  The pump was started and run at a steady rate of 1 
mL/min for 30 minutes to prepare the system.  The fluorescence detector was set 
for excitation at 313nm and emission at 353nm.   The autosampler was 
programmed to inject 100µL into the line.  The system would record the emission 
for 30 minutes and then inject the next sample.  Based on the standard curve, the 
peak at approximately 20 minutes is the derivatized potassium cyanate. 
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Appendix D 
 
1. Calculation to determine the cyanate concentration 
 
The standard curve samples were derivatized and run through the HPLC in the 
method described previously.  The area under the curve (AUC) was determined by 
the HPLC control software (TurboChrom).  The AUC for the cyanate peak was 
entered into Microsoft Excel and plotted against the known concentrations.  The 
Microsoft Excel slope function was then used to determine the slope (m) and the 
Microsoft Excel intercept function was used to determine the intercept (b).   
 
The experiment samples were then derivatized and run through the HPLC in the 
method described previously.  The AUC for the cyanate peak was then entered into 
Microsoft Excel.  Using the straight line equation of y = mx +b, the concentration of 
the experiment sample was able to be determined. 
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Appendix E 
1. Working Solutions for Glutathione Analysis 
0.2 mM m-Cresol Purple 
m-Cresol is a pH indicator and also functions as a preservative for the GSH. 
8.1 mg of m-cresol purple was dissolved in deionized high purity water for a total 
volume of 100 mL.  At room temperature, the solution has a shelf life of 1 month. 
IAA / m-cresol solution (100 mM Iodoacetic Acid in 0.2 mM m-cresol purple) 
IAA reacts with GSH to form a s-carboxylmethyl derivative which is ultimately 
fluorescence labeled with FDNB and detected in the fluorescence detector.   
20.8 mg of IAA sodium salt was dissolved in 1 mL of 0.2 mM m-cresol purple 
solution.  This solution has a very short shelf life, and was created each day  
PCA / BPDS working solution (1.0 mM BPDS in 10:1 PCA solution) 
PCA prevents GSH from being oxidized and also to precipitate protein.  BPDS is 
a metal chelator.   
14.3 mL of 70% Perchloric Acid (PCA) was added with care to roughly 75 mL of 
deionized high purity water while frequently stirring.  53.6 mg of 
Bathophenanthroline disulfonic acid (BPDS) dissolved in the PCA solution.  The 
total volume was brought up to 100 mL with deionized water.  At room 
temperature this solution has a shelf life of up to 1 month. 
BPDS Solution (15 mM BPDS in H2O) 
160 mg of BPDS was dissolved deionized water for a total volume of in 20 mL.  
At room temperature this solution has a shelf life of up to 1 month. 
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KOH/KHCO3 Solution 
The KOH/KHCO3 solution is added to adjust the pH of the solutions. 
10 M KOH is made by dissolving 56.1 g of KOH in 100 mL of deionized high 
purity water. 
3 M KHCO3 is made by dissolving 60.1 g KHCO3 in 200 mL of deionized high 
purity water. 
40 mL of 10 M KOH is then combined with 160 mL of 3 M KHCO3.  At room 
temperature this solution has a shelf life of up to 1 month. 
FDNB Solution (1% (v/v) 1/fluoro-2,4-dinitrobenzene in HPLC grade ethanol) 
FDNB is a fluorescence compound that binds with the IAA-GSH compound (s-
carboxylmethyl derivatives) to form n-dinitrophenyl-s-carboxymethyl derivatives 
which are detected via the fluorescence detector. 
0.5 mL of FDNB was added to 49.5 mL of ethanol.  This solution can be stored at 
4°C in a dark container with foil for up to 1 month. 
γ-Glu-Glu stock solution (4.0 mM γ-Glutamyl-Glutamate (γ-Glu-Glu)) 
γ-Glu-Glu was used as an internal standard.   11.04 mg of γ-Glu-Glu weighed out 
and dissolved in 9 mL of 15 mM BPDS solution.  The total volume of solution is 
then diluted to 10 mL with deionized water.  This solution was stored in aliquots 
of 50 µL and 100 µL in a microcentrifuge tube at -20°C for up to 6 months. 
γ-Glu-Glu working solution 
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900 µL PCA/BPDS (0.4 mM) is added to 100 µL γ-Glu-Glu (4 mM) stock that 
was removed from the freezer.  Enough should be made for the entire day and 
mixed to confirm uniformity. 
GSH working solution 
The working solution is made so that when added to the various tubes, they all 
receive the same amount of internal standard. 
900 µL PCA/BPDS (0.4 mM) is added to 100 µL γ-Glu-Glu (4 mM) stock that 
was removed from the freezer.  Enough should be made for the entire day and 
mixed to confirm uniformity. 
Mobile phase A (4:1 methonol water) 
 3.2 L HPLC grade methanol (Filtered) 
 0.8 L HPLC grade water (Filtered) 
Acetate Stock Solution 
 Add 378 mL glacial acetic acid to 122 mL HPLC grade water 
 While heating and stirring, slowly add 272g sodium acetate trihydrate 
Mobile phase B 
 3.2 L mobile phase A 
 0.8 L Acetate Stock Solution 
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Appendix F 
1. Method to Prepare GSH and GSSG Standards 
Standards 
 Standard with concentrations of 35, 70, 105, and 140 of GSH and GSSG µL were 
run in duplicate.  Two other standards were created that contained only 70 µL of GSH or 
only 70 µL of GSSG.  This was to confirm GSH was not be oxidized to GSSG during the 
analysis.   
Approximately 1.5 mg GSH was added to a 1.5 mL microcentrifuge tube and kept 
on ice.  The exact weight was noted in the lab notebook.  A sufficient amount of BPDS 
solution was then added to the tube to have a final concentration of 1.23 mg/mL.  For 
example, if 1.5 mg of GSH was added to the tube.  1.5 divided by the MW of GSH (1.23) 
would be 1.22 mL of BPDS solution to add to make the final. 150 µL of this GSH stock 
solution is then added to 1350 µL of PCA/BPDS solution in a 2mL microcentrifuge tube 
for the GSH working solution. 
Approximately 3 mg GSSG was added to a 1.5 mL microcentrifuge tube and kept 
on ice.  The exact weight was noted in the lab notebook.  A sufficient amount of BPDS 
solution was then added to the tube to have a final concentration of 2.45 mg/mL.  For 
example, if 3 mg of GSSG was added to the tube.  3 divided by the MW of GSSG (2.45) 
would be 1.23 mL of BPDS solution to add to make the final. 150 µL of this GSSG stock 
solution is then added to 1350 µL of PCA/BPDS solution in a 2mL microcentrifuge tube 
for the GSSG working solution. 
 PCA/BPA is first added to each tube based on the quantity in the table 5.  This 
was followed by 50 µL of γ-Glu-Glu working solution.  Volumes of the GSH working 
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solution and GSSG working solutions were then added based on the volumes listed in the 
table 5. 
Table 5 – Volumes for glutathione standard curve determination 
 GSH 
Tube 
Tube 
35 
Tube 70 Tube 
105 
Tube 
140 
Tube 
GSSG 
PCA/BPDS, µL 380 380 310 240 170 380 
γ-Glu-Glu working 
solution ,µL  50 50 50 50 50 50 
GSH working 
solution, µL 70 35 70 105 140 0 
GSSG working 
solution, µL 0 35 70 105 140 70 
 
The tubes were then mixed on a vortex and 200 µL of the supernatant was 
removed and placed into a new 1.5 mL microcentrifuge tube. 
 To each of the supernatant samples, 50 µL of the IAA/m-cresol purple solution 
was added.  The samples were then adjusted to have a pH of 8-9 by using KOH/KHCO3 
Solution.  The KOH/KHCO3 solution should be added at no more than 50 µL increments 
to prevent the sample from bubbling over.  Typically a total of 130 µL was added to each 
sample.  The solution should turn purple and stay purple after it is vortexed.  The samples 
were the covered in a thick black cloth and put into a laboratory drawer for one hour.  
The purpose of this step is for the iodoacetic acid to react with the thiols in order to form 
S-carboxymethyl derivatives.  The purpose of the m-cresol purple was not only to 
function as a pH indicator, but also as a preservative.   
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 The reaction of the iodoacetic acid with the thiols and forming S-carboxymethyl 
derivatives of thiols eliminated the potential for thiol disulfide interchange.  This could 
have occurred within a few minutes after the cells were disrupter.  
 An equal volume of FDNB solution was added to each sample (usually 380 µL).  
They were then incubated in a dark environment at room temperature for 18-24 hours.  
The tubes were covered by a thick black cloth and put into a lab drawer in order to keep 
the samples in complete darkness. 
 The purpose of adding the FDNB was to form 2,4-dinitrophenyl derivatives.  At 
4°C, these samples were stable for at least two weeks. 
 After 24 hours in room temperature darkness, the samples were placed in a 
13,000X centrifuge for 20 minutes.  One hundred µL of the supernatant was added to the 
autosampler tubes and placed into the autosampler.  In addition to samples, a standard 
curve, GSH only, and GSSG only samples were analyzed via HPLC with UV/Vis dection 
at a wavelength of 365nm.  Each run took about 45 minutes.  Using the standard curve, 
the concentration of GSH and GSSG was calculated for each sample.   
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Appendix G 
1. Glutathione Analysis – High Performance Liquid Chromatography 
Solvent and Gradient System 
 Reverse-phase ion-exchange was used to separate the compounds with a bonded 
phase packing that contains a bonded surface that was coated with 3-aminopropyl groups.  
The column used was 20cm x 4.6mm with 5µm exsil silica derivatized with 3-
aminopropyltriethoxy-silane purchased from CEL Associates.   The excess of 1-fluoro-
2,4-dinitrobenzene is rapidly eluted using methanol and appeared as a large peak within 
the first few minutes of the run.  Methanol also eluted excess concentrations of 4-
dinitrophenol derivatives of basic and neutral amino acids as well as 2,4-dinitrophenol.  
In order to maintain the bonded phase amino groups in the protonated form, acetic acid at 
a pH of 4.5-4.6 was used.  This permits selective ion elution of the acidic dinitrophenol 
derivatives along with the increasing concentration of sodium acetate. 
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Gradient 
 The flow rate of the two pumps (one for each mobile phase) was adjusted by a 
controller to get the following ratios but keep a constant flow of 1.0 mL/min. 
 0-8 minutes 
80% Mobile Phase A 
20% Mobile Phase B 
 8-28 minutes 
Start linear gradient moving from current ratio to 100% Mobile phase  
 28-40 minutes – 
Start linear gradient moving from current ratio to 80% A / 20% B 
 40-45 minutes 
80% Mobile Phase A 
20% Mobile Phase B 
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Appendix H 
1. Calculations for determining GSH and GSSG in samples 
The standards were run in the HPLC using the method described previously.  
From this, a standard curve was developed which allows for the calculation of the 
unknown concentrations of GSH and GSSG.  The area under the curve (AUC) for the y-
glu-glu, GSH, and GSSG peaks were entered into Microsoft Excel and plotted against the 
known concentrations.  The Microsoft Excel slope function was then used to determine 
the slope (m) and the Microsoft Excel intercept function was used to determine the 
intercept (b).   
The experiment samples were then derivatized and run through the HPLC in the 
method described previously.  The AUC for the y-glu-glu, GSH, and GSSG peaks were 
determined by the HPLC control software (TurboChrom).  The AUC was then entered 
into Microsoft Excel.  Using the straight line equation of y = mx +b, the concentration of 
the experiment sample was able to be determined 
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Appendix I 
1. HPLC Column Retention Times 
HPLC Chromatograph Retention Times for n-dinitrophenyl-S-carboxymethyl derivatives 
Compound Retention Time 
y-Glutamyl Glutamate (Internal Standard) 15 – 20 
Glutathione (GSH) 18 – 22 
Glutathione Disulfide (GSSG) 22 - 25 
  
 
Retention Times will vary depending on the age of the HPLC column. 
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Appendix J 
1. Example  HPLC Chromatographs and standard curves 
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Appendix K 
1. Working Solutions for Cyanide Analysis and standard curve 
Sodium Hydrogen Phosphate (NaH2PO4) 
13.8 g NaH2PO4 weighed out and placed into a 100 mL volumetric flask.  
Deionized water was used to fill the volume of the volumetric flask.  When 
refrigerated this solution has a shelf life of up to 1 year. 
Chloramine T 
125 mg of Chloramine T weighed out and  placed into a 50 mL volumetric flask.  
Deionized water was used to fill the volume of the volumetric flask.  When 
refrigerated this solution has a shelf life of up to 6 months. 
Barbituric Acid Reagent 
7.5 mL of pyridine was added to 1.5g of barbituric acid in a 25 mL volumetric 
flask.  This solution was mixed and 1.5 mL of concentrated hydrochloric acid 
(HCl) was added.  The solution was mixed and swirled repeatedly.  The volume 
of the volumetric flask was filled and diluted with deionized water.  The Solution 
was mixed frequently over a period of 30 minutes until solution is totally 
dissolved.  When refrigerated this solution has a shelf life of up to 3 months. 
0.1 N NaOH 
50 mL of 1N NaOH aqueous solution was added to a 500 mL volumetric flask.  
The volumetric flask was then diluted with deionized water.  At room 
temperature, this solution has a shelf life of up to 6 months. 
0.2 N H2SO4 
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2.8 mL of concentrated sulfuric acid was added to a 500 mL volumetric flask.  
The volumetric flask was diluted with deionized water.  At room temperature, this 
solution has a shelf life of up to 6 months. 
10% H2SO4 
50 mL of concentrated sulfuric acid was added to a 500 mL volumetric flask.  The 
volumetric flash was diluted with deionized water.  At room temperature this 
solution has a shelf life of up to 1 year. 
Cyanide Stock Standard 
250 mg of potassium cyanide was weighed out.  It was then placed into a one liter 
volumetric flask.  The volumetric flask was diluted with 0.1 NaOH.  When 
refrigerated this solution has a shelf life of up to 1 year. 
Working Cyanide Standard 
1.0 mL of the stock cyanide standard was added to a 100 mL volumetric flask.  
The volumetric flask was then diluted with 0.1 NaOH.  When refrigerated this 
solution has a shelf life of up to 6 months. 
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Appendix L – Lung GSH Concentration 
Group Concentration 
 (µmol / g tissue) 
Standard Error Number of animals 
Vehicle 1866 88 10 
2-CAN 1480* 150 12 
CYP 1908 72 9 
CYP + 2-CAN 1432* 38 11 
 
* Statistically significant compared to vehicle.  p<0.05 
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Appendix M – Lung GSSG Concentration 
  
Group Concentration 
 (µmol / g tissue) 
Standard Error Number of animals 
Vehicle 52 6 7 
2-CAN 49 7 8 
CYP 85 17 7 
CYP + 2-CAN 77 13 11 
 
No statistically significant changes among any of the groups.
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Appendix N – Liver GSH Concentration 
Group Concentration 
 (µmol / g tissue) 
Standard Error Number of animals 
Vehicle 6989 278 10 
2-CAN 3913* 189 10 
CYP 6434 149 9 
CYP + 2-CAN 3524* 213 11 
 
* Statistically significant compared to vehicle.  p<0.05 
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Appendix O – Liver GSSG Concentration 
Group Concentration 
 (µmol / g tissue) 
Standard Error Number of animals 
Vehicle 94 15 11 
2-CAN 120 13 9 
CYP 90 10 8 
CYP + 2-CAN 91 20 10 
 
No statistically significant changes among any of the groups.
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Appendix P – Blood Cyanide Concentration 
Group Concentration 
 (µg / mL blood) 
Standard Error Number of animals 
Vehicle 0.027 0.002 7 
2-CAN 0.057* 0.009 7 
CYP 0.025 0.002 7 
CYP + 2-CAN 0.046 0.007 6 
 
* Statistically significant compared to vehicle.  p<0.05 
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Appendix Q – Plasma Cyanate Concentration 
Group Concentration 
 (nmol/L) 
Standard Error Number of animals 
Vehicle 88.9 15.7 10 
2-CAN 435.7* 81.7 11 
CYP 69.3 11.1 9 
CYP + 2-CAN 194.4** 31.2 10 
 
* Statistically significant compared to vehicle.  p<0.05;  
** Statistically significant compared to 2-CAN group.  p<0.05 
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Appendix R – Time to onset of hind-limb paralysis 
Group Minutes Standard Error Number of animals 
2-CAN 6.4 0.92 5 
CYP + 2-CAN 16* 1.45 5 
 
* Statistically significant compared to 2-CAN group.  p<0.05 
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